3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Doxorubicin
5
pazopanib
4
Ifosfamide
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Conformal
2
Radiotherapy
2
tremelimumab
1
temsirolimus
1
sintilimab
1
saracatinib
1
sapanisertib
1
romidepsin
1
olaratumab
1
liposomal doxorubicin
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
Watchful Waiting
1
Surgical Procedures, Operative
1
Sorafenib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Polymerase Chain Reaction
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Methotrexate
1
MLN 8237
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Histiocytoma, Malignant Fibrous
×
ribociclib
×
Clear all
No trials found.